{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T21:45:53Z","timestamp":1791755153698,"version":"4.3.4"},"reference-count":53,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2027,1,1]],"date-time":"2027-01-01T00:00:00Z","timestamp":1798761600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["9456"],"award-info":[{"award-number":["9456"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001411","name":"Indian Council of Medical Research","doi-asserted-by":"publisher","award":["12369"],"award-info":[{"award-number":["12369"]}],"id":[{"id":"10.13039\/501100001411","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cellular Signalling"],"published-print":{"date-parts":[[2027,1]]},"DOI":"10.1016\/j.cellsig.2026.112913","type":"journal-article","created":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T15:00:08Z","timestamp":1790434808000},"page":"112913","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["A Thieno[3,2-D] pyrimidine class of p110\u03b1\/GDH1 dual inhibitor SBS-873 suppresses TNBC growth by inhibiting PI3K\/mTOR signaling and inducing ferroptosis through glutathione depletion"],"prefix":"10.1016","volume":"149","author":[{"given":"Biswajit","family":"Dey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Essha","family":"Chatterjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sivkan Kaur","family":"Nanda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankush","family":"Bansode","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santanu","family":"Basak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahul","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoshiyar","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nandkumar","family":"Doijad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhagyashri N.","family":"Wadje","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pankaj Kumar","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pradeep Kumar","family":"Naik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandip B.","family":"Bharate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9287-1836","authenticated-orcid":false,"given":"Santosh Kumar","family":"Guru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cellsig.2026.112913_bb0005","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Ferlay","year":"2024"},{"issue":"2019","key":"10.1016\/j.cellsig.2026.112913_bb0010","first-page":"44","article-title":"Molecular classification of breast cancer : a retrospective cohort study","volume":"49","author":"Khinai","year":"2020","journal-title":"Ann. Med. Surg."},{"issue":"92","key":"10.1016\/j.cellsig.2026.112913_bb0015","article-title":"Targeting PI3K inhibitor resistance in breast cancer with metabolic drugs","volume":"10","author":"Gremke","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"issue":"1","key":"10.1016\/j.cellsig.2026.112913_bb0020","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jcrpr.2015.10.005","article-title":"Long-term survival and stage I breast cancer subtypes","volume":"3","author":"Cheng","year":"2016","journal-title":"J. Cancer Res. Pract."},{"key":"10.1016\/j.cellsig.2026.112913_bb0025","first-page":"321","article-title":"Regulation of cancer stem cells in triple negative breast cancer","volume":"4","author":"Fultang","year":"2021","journal-title":"Cancer Drug Resist."},{"issue":"957","key":"10.1016\/j.cellsig.2026.112913_bb0030","first-page":"1","article-title":"Mechanisms of chemotherapy resistance in triple-negative breast cancer-how we can rise to the challenge","volume":"8","author":"Nedeljkovi","year":"2019","journal-title":"Cells"},{"key":"10.1016\/j.cellsig.2026.112913_bb0035","doi-asserted-by":"crossref","unstructured":"J. K. Khan, Jain VK, Rizwanullah M, Ahmad J, \u201cPI3K\/AKT\/mTOR pathway inhibitors in triple-negative breast cancer: a review on drug discovery and future challenges,\u201d Drug Discov. Today, vol. 24, no. 11, pp. 2181\u20132191, doi:https:\/\/doi.org\/10.1016\/j.drudis.2019.09.001.","DOI":"10.1016\/j.drudis.2019.09.001"},{"issue":"2232","key":"10.1016\/j.cellsig.2026.112913_bb0040","first-page":"1","article-title":"The PI3K \/ Akt \/ mTOR signaling pathway in triple-negative breast cancer : a resistance pathway and a prime target for targeted therapies","volume":"17","author":"Hassan","year":"2025","journal-title":"Cancers (Basel)."},{"issue":"44","key":"10.1016\/j.cellsig.2026.112913_bb0045","doi-asserted-by":"crossref","first-page":"16296","DOI":"10.1073\/pnas.0607899103","article-title":"The p110 alpha isoform of PI3K is essential for proper growth factor signaling and oncogenic transformation","volume":"103","author":"Zhao","year":"2006","journal-title":"PNAS"},{"issue":"8","key":"10.1016\/j.cellsig.2026.112913_bb0050","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.3390\/cancers16081561","article-title":"NGS-guided precision oncology in breast cancer and gynecological tumors-a retrospective molecular tumor board analysis","volume":"16","author":"Tumors","year":"2024","journal-title":"Cancers (Basel)."},{"key":"10.1016\/j.cellsig.2026.112913_bb0055","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1158\/2159-8290.CD-23-0704","article-title":"Allosteric PI3K \u03b1 inhibition overcomes on-target resistance to Orthosteric inhibitors mediated by secondary PIK3CA mutations","volume":"14","author":"Varkaris","year":"2024","journal-title":"Cancer Discov."},{"issue":"10","key":"10.1016\/j.cellsig.2026.112913_bb0060","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/s41573-021-00209-1","article-title":"PI3K inhibitors are finally coming of age","volume":"20","author":"Vanhaesebroeck","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"issue":"164","key":"10.1016\/j.cellsig.2026.112913_bb0065","first-page":"1","article-title":"Targeting PI3K family with small - molecule inhibitors in cancer therapy\u00a0: current clinical status and future directions","volume":"23","author":"Li","year":"2024","journal-title":"Mol. Cancer"},{"issue":"9","key":"10.1016\/j.cellsig.2026.112913_bb0070","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1158\/2159-8290.CD-21-1696","article-title":"Alpelisib monotherapy for PI3K-altered, Pretreated advanced breast Cancer: a phase II study","volume":"12","author":"Savas","year":"2022","journal-title":"Cancer Discov."},{"issue":"2","key":"10.1016\/j.cellsig.2026.112913_bb0075","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1093\/annonc\/mdw562","article-title":"A randomized adaptive phase II\/III study of buparlisib, a pan-class I PI3K inhibitor, combined with paclitaxel for the treatment of HER2- advanced breast cancer (BELLE-4)","volume":"28","author":"Mart\u00edn","year":"2017","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.cellsig.2026.112913_bb0080","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1158\/2159-8290.CD-23-0944","article-title":"Discovery and clinical proof-of-concept of RLY-2608, a first-in-class mutant-selective allosteric PI3K\u03b1 inhibitor that decouples antitumor activity from hyperinsulinemia","volume":"14","author":"Varkaris","year":"2024","journal-title":"Cancer Discov."},{"issue":"11","key":"10.1016\/j.cellsig.2026.112913_bb0085","doi-asserted-by":"crossref","first-page":"2432","DOI":"10.1158\/2159-8290.CD-23-0396","article-title":"STX-478, a mutant-selective, allosteric PI3K\u03b1 inhibitor spares metabolic dysfunction and improves therapeutic response in PI3K\u03b1-mutant xenografts","volume":"13","author":"Buckbinder","year":"2023","journal-title":"Cancer Discov."},{"key":"10.1016\/j.cellsig.2026.112913_bb0090","first-page":"97","article-title":"A novel dual PI3K alpha\/ mTOR inhibitor PI-103 with high antitumor activity in non-small cell lung cancer cells","volume":"24","author":"Zou","year":"2009","journal-title":"Int. J. Mol. Med."},{"issue":"12","key":"10.1016\/j.cellsig.2026.112913_bb0095","doi-asserted-by":"crossref","first-page":"5840","DOI":"10.1158\/0008-5472.CAN-06-4615","article-title":"Pharmacologic characterization of a potent inhibitor of class I Phosphatidylinositide 3-kinases","volume":"67","author":"Raynaud","year":"2007","journal-title":"Cancer Res."},{"issue":"20","key":"10.1016\/j.cellsig.2026.112913_bb0100","doi-asserted-by":"crossref","first-page":"21282","DOI":"10.1021\/acs.jmedchem.5c01164","article-title":"Discovery of 2-(4-ureido-piperidin-1-yl)-4-morpholinothieno [3,2-D] pyrimidines as orally bioavailable phosphoinositide-3-kinase inhibitors with in vitro and in vivo antitumor efficacy in triple-negative breast cancer","volume":"68","author":"Mohammed","year":"2025","journal-title":"J. Med. Chem."},{"issue":"W1","key":"10.1016\/j.cellsig.2026.112913_bb0105","doi-asserted-by":"crossref","first-page":"W98","DOI":"10.1093\/nar\/gkx247","article-title":"GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses","volume":"45","author":"Tang","year":"2017","journal-title":"Nucleic Acids Res."},{"issue":"2","key":"10.1016\/j.cellsig.2026.112913_bb0110","article-title":"PlotROC: a tool for plotting ROC curves","volume":"79","author":"Sachs","year":"2017","journal-title":"J. Stat. Softw."},{"key":"10.1016\/j.cellsig.2026.112913_bb0115","series-title":"Crystal Structures of PI3K \u03b1 Complexed with PI103 and Its Derivatives: New Directions for Inhibitors Design","first-page":"138","author":"Zhao","year":"2014"},{"issue":"02","key":"10.1016\/j.cellsig.2026.112913_bb0120","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S0022-2836(02)00161-4","article-title":"The structure of apo human glutamate dehydrogenase details subunit communication and allostery","volume":"2836","author":"Smith","year":"2002","journal-title":"J. Mol. Biol."},{"issue":"PB","key":"10.1016\/j.cellsig.2026.112913_bb0125","article-title":"Evaluation of decursin and its isomer decursinol angelate as potential inhibitors of human glutamate dehydrogenase activity through in silico and enzymatic assay screening","volume":"151","author":"Ngullie","year":"2022","journal-title":"Comput. Biol. Med."},{"issue":"39","key":"10.1016\/j.cellsig.2026.112913_bb0130","doi-asserted-by":"crossref","first-page":"34164","DOI":"10.1074\/jbc.M111.268599","article-title":"Green tea polyphenols control dysregulated glutamate dehydrogenase in transgenic mice by hijacking the ADP activation site *","volume":"286","author":"Li","year":"2011","journal-title":"J. Biol. Chem."},{"issue":"10","key":"10.1016\/j.cellsig.2026.112913_bb0135","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2013.399","article-title":"Autophagy triggered by magnolol derivative negatively regulates angiogenesis","volume":"4","author":"Kumar","year":"2013","journal-title":"Cell Death Dis."},{"issue":"14","key":"10.1016\/j.cellsig.2026.112913_bb0140","doi-asserted-by":"crossref","first-page":"2886","DOI":"10.1158\/0008-5472.CAN-14-2312","article-title":"Secalonic acid-D represses HIF1\u03b1\/VEGF-mediated angiogenesis by regulating the Akt\/mTOR\/p70S6K signaling cascade","volume":"75","author":"Guru","year":"2015","journal-title":"Cancer Res."},{"issue":"December 2016","key":"10.1016\/j.cellsig.2026.112913_bb0145","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.redox.2017.01.016","article-title":"Inhibition of cancer migration and invasion by knocking down delta-5-desaturase in COX-2 overexpressed cancer cells","volume":"11","author":"Yang","year":"2017","journal-title":"Redox Biol."},{"issue":"June","key":"10.1016\/j.cellsig.2026.112913_bb0150","first-page":"1","article-title":"Anticancer activity of RM-3-22: a TAZQ-based hydroxamic acid derivative targeting NSCLC in vitro and in vivo","volume":"16","author":"Chatterjee","year":"2025","journal-title":"Front. Pharmacol."},{"issue":"01","key":"10.1016\/j.cellsig.2026.112913_bb0155","first-page":"1","article-title":"A simple microplate assay for reactive oxygen species generation and rapid cellular protein normalization","volume":"11","author":"Neville","year":"2021","journal-title":"Bio-Protoc."},{"issue":"1","key":"10.1016\/j.cellsig.2026.112913_bb0160","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/0003-9861(59)90090-6","article-title":"Tissue sulfhydryl groups","volume":"82","author":"Ellman","year":"1959","journal-title":"Arch. Biochem. Biophys."},{"issue":"2","key":"10.1016\/j.cellsig.2026.112913_bb0165","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/0003-2697(79)90738-3","article-title":"Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction","volume":"95","author":"Ohkawa","year":"1979","journal-title":"Anal. Biochem."},{"issue":"11","key":"10.1016\/j.cellsig.2026.112913_bb0170","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/nrclinonc.2016.66","article-title":"Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease","volume":"13","author":"Bianchini","year":"2016","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.cellsig.2026.112913_bb0175","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1158\/2159-8290.CD-18-1177","article-title":"Insights into molecular classifications of triple-negative breast cancer\u202f: improving patient selection for treatment","volume":"9","author":"Garrido-castro","year":"2019","journal-title":"Cancer Discov."},{"issue":"15","key":"10.1016\/j.cellsig.2026.112913_bb0180","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1158\/1078-0432.CCR-06-3045","article-title":"Triple-negative breast Cancer: clinical features and patterns of recurrence","volume":"13","author":"Dent","year":"2007","journal-title":"Clin. Cancer Res."},{"issue":"406","key":"10.1016\/j.cellsig.2026.112913_bb0185","first-page":"1","article-title":"PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors","volume":"16","author":"Lehmann","year":"2014","journal-title":"Breast Cancer Res."},{"issue":"5","key":"10.1016\/j.cellsig.2026.112913_bb0190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.21037\/atm-21-698","article-title":"PIK3CA mutation confers resistance to chemotherapy in triple-negative breast cancer by inhibiting apoptosis and activating the PI3K \/ AKT \/ mTOR signaling pathway","volume":"9","author":"Hu","year":"2021","journal-title":"Ann. Transl. Med."},{"issue":"14","key":"10.1016\/j.cellsig.2026.112913_bb0195","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1158\/1078-0432.CCR-20-4879","article-title":"Clinical and biomarker results from phase I\/II study of PI3K inhibitor alpelisib plus nab-paclitaxel in HER2-negative metastatic breast cancer","volume":"27","author":"Sharma","year":"2022","journal-title":"Clin. Cancer Res."},{"issue":"6","key":"10.1016\/j.cellsig.2026.112913_bb0200","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2025.112551","article-title":"Lifting the veil on tumor metabolism\u00a0: a GDH1-focused perspective","volume":"28","author":"Zhou","year":"2025","journal-title":"ISCIENCE"},{"issue":"1","key":"10.1016\/j.cellsig.2026.112913_bb0205","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12967-015-0500-6","article-title":"Glutamate dehydrogenase is a novel prognostic marker and predicts metastases in colorectal cancer patients","volume":"13","author":"Liu","year":"2015","journal-title":"J. Transl. Med."},{"issue":"3","key":"10.1016\/j.cellsig.2026.112913_bb0210","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1093\/neuonc\/noae222","article-title":"Glutamate dehydrogenase 1-catalytic glutaminolysis feedback activates EGFR\/PI3K\/AKT pathway and reprograms glioblastoma metabolism","volume":"27","author":"Yang","year":"2025","journal-title":"Neuro Oncol."},{"issue":"6","key":"10.1016\/j.cellsig.2026.112913_bb0215","first-page":"4973","article-title":"SIRT4 suppresses the PI3K\/Akt\/NF-\u03baB signaling pathway and attenuates HUVEC injury induced by oxLDL","volume":"19","author":"Tao","year":"2019","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.cellsig.2026.112913_bb0220","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2023.216064","article-title":"The PIK3CA-E545K-SIRT4 signaling axis reduces radiosensitivity by promoting glutamine metabolism in cervical cancer","volume":"556","author":"Jiang","year":"2023","journal-title":"Cancer Lett."},{"issue":"1","key":"10.1016\/j.cellsig.2026.112913_bb0225","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-026-08601-8","article-title":"AKT1 phosphorylates PRMT7 to promote GLUD1 methylation and gastric cancer progression","volume":"17","author":"Cui","year":"2026","journal-title":"Cell Death Dis."},{"issue":"228","key":"10.1016\/j.cellsig.2026.112913_bb0230","first-page":"1","article-title":"Triple-negative breast cancer progression and drug resistance in the context of epithelial \u2013 mesenchymal transition","volume":"17","author":"B\u0142aszczak","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.cellsig.2026.112913_bb0235","first-page":"593","article-title":"Suppression of triple-negative breast cancer metastasis by pan- DAC inhibitor panobinostat via inhibition of ZEB family of EMT master regulators","volume":"145","author":"Hoang","year":"2015","journal-title":"Breast Cancer Res. Treat."},{"issue":"428","key":"10.1016\/j.cellsig.2026.112913_bb0240","first-page":"1","article-title":"Metabolic reprogramming in triple-negative breast cancer","volume":"10","author":"Sun","year":"2020","journal-title":"Front. Oncol."},{"issue":"3","key":"10.1016\/j.cellsig.2026.112913_bb0245","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1111\/bjh.18884","article-title":"Glutamate dehydrogenase 1: a novel metabolic target in inhibiting acute myeloid leukaemia progression","volume":"202","author":"Ma","year":"2023","journal-title":"Br. J. Haematol."},{"issue":"8","key":"10.1016\/j.cellsig.2026.112913_bb0250","doi-asserted-by":"crossref","first-page":"4900","DOI":"10.1111\/jcmm.14511","article-title":"Molecular mechanisms of ferroptosis and its role in cancer therapy","volume":"23","author":"Xu","year":"2019","journal-title":"J. Cell. Mol. Med."},{"issue":"12","key":"10.1016\/j.cellsig.2026.112913_bb0255","doi-asserted-by":"crossref","DOI":"10.1002\/mco2.70493","article-title":"CD36 inhibits triple-negative breast Cancer progression by transcriptionally upregulating Caveolin-1 and promoting lipid-reactive oxygen species-related ferroptosis","volume":"6","author":"Wu","year":"2025","journal-title":"MedComm"},{"key":"10.1016\/j.cellsig.2026.112913_bb0260","article-title":"CrVDAC3 alleviates ferroptosis by impeding HSPB1 ubiquitination and confers trastuzumab deruxtecan resistance in HER2-low breast cancer","volume":"77","author":"Zou","year":"2024","journal-title":"Drug Resist. Updat. Rev. Comment. Antimicrob. Anticancer Chemother."},{"issue":"3","key":"10.1016\/j.cellsig.2026.112913_bb0265","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1158\/0008-5472.CAN-24-1941","article-title":"Ferroptotic neutrophils induce immunosuppression and chemoresistance in breast Cancer","volume":"85","author":"Zeng","year":"2025","journal-title":"Cancer Res."}],"container-title":["Cellular Signalling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0898656826005723?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0898656826005723?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T21:09:34Z","timestamp":1791752974000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0898656826005723"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2027,1]]},"references-count":53,"alternative-id":["S0898656826005723"],"URL":"https:\/\/doi.org\/10.1016\/j.cellsig.2026.112913","relation":{},"ISSN":["0898-6568"],"issn-type":[{"value":"0898-6568","type":"print"}],"subject":[],"published":{"date-parts":[[2027,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Thieno[3,2-D] pyrimidine class of p110\u03b1\/GDH1 dual inhibitor SBS-873 suppresses TNBC growth by inhibiting PI3K\/mTOR signaling and inducing ferroptosis through glutathione depletion","name":"articletitle","label":"Article Title"},{"value":"Cellular Signalling","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cellsig.2026.112913","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"112913"}}